Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line or Third-line Lower Lower Risk Myelodysplastic Syndrome
Conditions
Interventions
Sponsor
Opsona Therapeutics Ltd.
Collaborators
- [object Object]
- [object Object]
- [object Object]
- [object Object]